Table 2.
Study endpoints according to molecular genetic and clinical prognostic subgroups
| Population | n | Median OS since surgery (months)a | Survival at 1 yearb | Survival at 2 yearsb | Survival at 3 yearsb |
|---|---|---|---|---|---|
| Overall | 331 | 23.1 (21.2, 25.4) |
89.3% (85.4, 92.2) |
46.2% (40.4, 51.8) |
25.4% (19.9, 31.3) |
| MGMT methylated | 131 | 34.7 (27.0, 40.7) |
94.5% (88.8, 97.3) |
66.7% (57.5, 74.4) |
46.4% (35.8, 56.3) |
| MGMT un-methylated | 162 | 19.8 (17.9, 21.7) |
86.4% (80.0, 90.8) |
32.1% (24.5, 9.9) |
11.0% (5.7, 18.2) |
| Gross total resection | 209 | 25.4 (21.8, 28.2) |
91.8% (87.1, 94.8) |
51.2% (43.9, 58.1) |
29.9% (22.6, 37.5) |
| Partial resection | 122 | 21.1 (19.1, 23.1) |
85.0% (77.2, 90.2) |
37.7% (28.6, 46.7) |
18.0% (10.5, 27.1) |
| KPS at baseline ≥ 90 | 234 | 23.7 (21.8, 26.7) |
94.0% (90.0, 96.4) |
49.2% (42.3, 55.8) |
26.6% (19.9, 33.8) |
| KPS at baseline < 90 | 97 | 19.8 (16.6, 23.9) |
77.8% (68.0, 84.9) |
38.8% (28.5, 49.0) |
22.1% (13.4, 32.2) |
| ALC > 800 | 161 | 23.6 (21.7, 28.2) |
89.9% (84.0, 93.7) |
49.5% (41.1, 57.4) |
28.7% (20.6, 37.3) |
| ALC ≤ 800 | 170 | 21.6 (19.9, 25.2) |
88.7% (82.8, 92.6) |
43.3% (35.4, 50.9) |
22.2% (15.0, 30.3) |
| Age < 50 years | 82 | 26.2 (21.1, 31.5) |
92.5% (84.2, 96.6) |
51.7% (39.9, 62.3) |
28.0% (16.4, 40.8) |
| Age ≥ 50 years | 249 | 22.4 (20.4, 24.1) |
88.2% (83.5, 91.7) |
44.4% (37.7, 50.8) |
24.6% (18.5, 31.2) |
aMedian overall survival (OS) in months of intent-to-treat (ITT) population, followed by 95% confidence interval in parentheses
bAnnual rates of percentage surviving in ITT population, followed by 95% confidence interval in parentheses